What is Incruse Ellipta?
Incruse Ellipta is an inhalation powder used to treat chronic obstructive pulmonary disease (COPD) in adults. Incruse Ellipta contains an active substance called umeclidinium bromide, which belongs to a group of medicines called bronchodilators. These block the tightening of the muscles around the airways, caused by COPD, making it easier for air to get in and out of lungs. When used regularly, it can help control your breathing difficulties and reduce the effects of COPD on your everyday life.
Incruse Ellipta should not be used to relieve a sudden attack of breathlessness or wheezing. If you get this sort of attack you must use a quick-acting reliever inhaler (such as salbutamol).
For further information on Incruse Ellipta (umeclidinium) and potential side effects, please see:
▼These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting side effects you may get.
If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via HPRA Pharmacovigilance, Website: www.hpra.ie. By reporting side effects you can help provide more information on the safety of this medicine.
Incruse and Ellipta are registered trademarks of the GlaxoSmithKline Group of Companies
